The role of tolvaptan in pulmonary hypertension
A retrospective study
Qiaoli Chen, PhD*, Heng Luo, MM*, Yuping Li, BS*,* "

Abstract
Pulmonary hypertension (PH) is a severe form of pulmonary vascular disease that can lead to right heart failure (RHF). Nearly 2-thirds of patients with PH die within 5 years. Studies suggest that a new diuretic medication, called tolvaptan (TLV), can be used to treat PH. However, there is still insufficient evidence to confirm its effectiveness. Therefore, we investigated the role of TLV in patients with PH. This retrospective study included 73 patients with PH hospitalized in Shanghai Pulmonary Hospital between November 2019 and March 2022. All patients received 7.5 to 15.0 mg of TLV for 3 to 21 days starting at admission, in addition to targeted drugs and traditional diuretic therapy. The outcomes included the blood pressure, urine and water intake volumes, electrolyte concentrations, and renal, liver, and cardiac function indexes before and after TLV treatment. In addition, we assessed the clinical symptoms and adverse reactions during the treatment. After TLV treatment, the water intake and urine volumes significantly increased, and body weight, diastolic blood pressure (DBP) and mean arterial pressure significantly decreased. Total bilirubin, direct bilirubin, N-terminal pro-brain natriuretic peptide, and serum uric acid (UA) levels after TLV treatment were significantly lower than before treatment. After TLV treatment, dyspnea significantly improved in 71 of 73 patients, and lower limb edema disappeared in 42 of 53 patients. No obvious adverse reactions occurred during the TLV treatment period. These results suggest that adding TLV to targeted drug and traditional diuretic therapies is effective for patients with PH. However, more data are required to support these findings.

Abbreviations: DBIL = direct bilirubin, DBP = diastolic blood pressure, NT-proBNP = N-terminal pro-brain natriuretic peptide, PAH = pulmonary arterial hypertension, PH = pulmonary hypertension, RHF = right heart failure, TBIL = total bilirubin, TLV = tolvaptan, UA = uric acid, WHO = World Health Organization.

Keywords: effectiveness, pulmonary hypertension, right heart failure, tolvaptan

1. Introduction
Pulmonary hypertension (PH) is a progressive disorder characterized by a chronic increase in pulmonary arterial pressure, frequently resulting in right heart failure (RHF) and potentially death.[1] PH is relatively common, affecting approximately 1% of all adults globally and 10% of those aged over 65 years.[2] The most recent the World Symposium on PH was modifying the clinical classification of PH into 5 groups: Group 1 is pulmonary arterial hypertension (PAH); Group 2 PH includes patients who have left hearts disease; Group 3 includes those who chronic lung diseases and/or hypoxia; Group 4 patients have pulmonary artery obstructions, including chronic thromboembolic PH; Group 5 is composed of a heterogenous group with unknown of multifactorial mechanisms of PH development.[3]

Tolvaptan (TLV) is an oral selective vasopressin type 2 receptor antagonist that inhibits vasopressin binding and increases the electrolyte-water clearance rate.[4] Some studies have demonstrated that TLV causes adverse reactions, such as a rapidly increasing serum sodium level.[5,6] Nonetheless, TLV has been widely used to treat hyponatremia, autosomal dominant polycystic kidney disease, and heart failure.[7–9]

Moreover, 1 study treated patients with PH-induced RHF with TLV for 12 weeks, finding that their weight decreased significantly, heart failure symptoms improved, and there were no obvious adverse reactions or hypernatremia.[10] However, using TLV for PH-induced RHF is still in the preliminary testing stage, and its safety and effectiveness have not been fully confirmed. Therefore, this study retrospectively analyzed correlations between the clinical indications of patients with PH and TLV in our hospital to provide some basis for TLV as a PH treatment.

2. Methods
2.1. Patients
We retrospectively analyzed the relevant clinical data of patients with PH from Shanghai Pulmonary Hospital.
Patients ≥ 18 years old diagnosed with PH by right heart catheterization were included. Furthermore, all included patients were administered 7.5 to 15 mg of TLV for 3 to 21 days starting at admission, in addition to targeted drug and traditional diuretic therapies. Patients with malignant tumors, severe liver dysfunction, severe kidney dysfunction, or incomplete records were excluded. We screened 136 patients, and 73 were enrolled based on the inclusion and exclusion criteria. The flow diagram of the retrospective analysis was presented in Figure 1.

2.2. Ethical approval

Shanghai Pulmonary Hospital approved the experimental design.

2.3. Data collections

We retrospectively collected the following data from the patients’ medical records: sex, age, height, body weight, alcohol consumption, smoking, mean pulmonary artery pressure, clinical classification of PH, the World Health Organization functional class, and hemoglobin, alanine transaminase, aspartate aminotransferase, total bilirubin (TBIL), direct bilirubin (DBIL), total bile acid, uric acid (UA), blood urea nitrogen, serum creatinine, Cystatin C, N-terminal pro-brain natriuretic peptide (NT-proBNP), the levels of potassium, sodium, chloride, and calcium, and heart rate, blood pressure, water intake, urine volume.

Two authors used a standardized form to gather patient-related information; the 2 result sets were checked against each other to ensure accuracy and reduce the risk of bias.

2.4. Statistical analyses

In the study, GraphPad Prism 5.01 software was adopted for statistical analysis of experiment data. Measurement data were expressed as mean ± standard deviation (SD); comparison between the 2 groups was tested by t test. In this study, P < .05 indicated statistical difference.

3. Results

Table 1 presents the baseline characteristics of the enrolled patients (n = 73); 68.49% patients were women. The mean age was 54.29 ± 15.68 (range, 22–83) years, and 31.51% patients were older than 65 years. The mean body mass index was 21.28 ± 0.49 kg/m². Three patients (4.11%) were found to have long-term smoking. The mean pulmonary artery pressure range of the enrolled patients was 27 to 108 mm Hg. Of all patients, 35 patients (47%) were found to have WHO group 1 PH, 4 patients (5.48%) were found to have WHO group 2 PH, 9 patients (12.33%) were found to have WHO group 3 PH, 7 patients (9.59%) were found to have WHO group 4 PH, 18 patients (24.66%) were found to have WHO group 5 PH. Sixty-seven PH patients (91.78%) were World Health Organization functional class III/IV in our study.

Most clinical indicators were comparable before and after TLV treatment (Table 2). The TBIL, DBIL, NT-proBNP, and serum UA levels were significantly lower after TLV treatment. TBIL level decreased from 31.86 ± 3.79 μmol/L to 24.67 ± 2.55 μmol/L (P = .001), DBIL level decreased from 16.34 ± 2.60 μmol/L to 13.49 ± 1.88 μmol/L (P = .018), NT-proBNP level decreased from 4396 ± 594.90 pg/mL to 2974 ± 437.00 pg/mL (P = .023), serum UA level decreased from 526.9 ± 22.99 μmol/L to 445.3 ± 26.18 μmol/L (P < .0001). However, serum potassium level significantly increased from 4.03 ± 0.07 mmol/L to 4.27 ± 0.06 mmol/L (P = .002) after TLV treatment. Other serum biomarker levels did not differ before and after treatment.

Furthermore, the diastolic blood pressure (DBP) and mean arterial pressure significantly decreased after TLV treatment (all P < .01) (Table 3). The water intake and urine volumes were significantly higher, and body weight and DBP were significantly lower after TLV treatment (all P < .001) (Table 4). Notably, dyspnea significantly improved in 71 of 73 patients, and lower limb edemas disappeared in 42 of 53 patients after TLV treatment. Finally, no obvious adverse reactions occurred during the TLV treatment period.

4. Discussion

In recent decades, the prognosis of patients with PH has significantly improved because of the considerable progress in targeted drugs.[11,12] PH-induced RHF is a crucial prognostic factor and the leading cause of death in patients with PAH.[1,13,14] There have been no treatment breakthroughs, but TLV has become a clinically effective treatment option in recent years for patients with PH-induced RHF.

This retrospective analysis found that the TBIL, DBIL, NT-proBNP, and serum UA levels were significantly lower after the TLV treatment. Additionally, the patient’s water intake and urine volumes were significantly higher, and body weight, DBP and mean arterial pressure were significantly lower after treatment. Moreover, dyspnea and lower limb edemas significantly improved after TLV treatment. These results suggest that routine therapies with TLV may be more effective than those without TLV in patients with PH.

We also found a significantly higher serum potassium concentration after TLV treatment; the serum sodium concentration also increased but not significantly. Therefore, monitoring the patient’s electrolyte concentrations is necessary during TLV treatment to prevent adverse reactions.

Pro-BNP is a pro-hormone primarily secreted by the ventricle and cleaved into NT-proBNP and active BNP. NT-proBNP has more clinical applications than active BNP owing to its longer half-life and better stability.[15] The European Society of Cardiology/European Respiratory Society guidelines recommend using NT-proBNP as part of a multiparametric assessment for prognostic and treatment goals for patients with PAH. In our study, the NT-proBNP level was significantly lower after TLV treatment, indicating that TLV may benefit RHF caused by PH.

UA is an end product of purine metabolism generated from xanthine by xanthine oxidoreductase and primarily excreted by the kidneys.[16] Some studies have reported an elevated UA level in hypoxic states, such as chronic heart failure and PH.[17–19] Furthermore, serum UA is a prognostic factor for adverse
outcomes and is associated with a higher 5-year mortality rate in patients with PH. Some studies have demonstrated that TLV increases the serum UA level by decreasing its renal clearance. Furthermore, water intake increased in these studies, which effectively reduced urinary UA supersaturation. However, our results demonstrated that adding TLV to targeted drug and traditional diuretic therapies decreased the serum UA level, perhaps because the patients’ water intake increased. Therefore, our study suggests that TLV may improve the prognosis and reduce the 5-year mortality rate for patients with PH.

Bilirubin is a metabolic end-product of heme degradation and an important endogenous antioxidant molecule. The TBIL level is a predictive risk factor for systolic heart failure and PAH, whereas DBIL can predict PH severity and outcomes. We found that adding TLV to targeted drug and traditional diuretic therapies reduced the serum TBIL and DBIL levels, suggesting PH severity and prognostic improvements.

Adverse reactions have been documented with TLV, such as a rapidly increasing serum sodium level. Some have also reported liver injury after TLV administration, characterized by elevated alanine aminotransferase and bilirubin levels and an increased UA level due to reduced renal excretion. In terms of diuretic mechanism, TLV did not increase the serum UA and bilirubin levels, perhaps caused by a decrease in volume after TLV urination or a rapidly increasing blood sodium level. However, these mechanisms require confirmation by clinical observation.

Our study has several limitations. First, this was a single-center analysis with a small number of patients. Second, we only documented a limited number of outcome measurements to assess TLV’s role in patients with PH. Third, bias may be inevitable since this was a retrospective and nonrandomized study. Hence, future follow-up studies should be multi-center analyses, include more patients, and analyze more outcome measurements to fully elucidate the role of TLV in patients with PH.

### Table 1
Baseline characteristics of the studied patients.

| Patient characteristics (n = 73) | Results |
|----------------------------------|---------|
| Age stratified, n (%)            |         |
| >65                              | 23 (31.51%) |
| ≤65                              | 50 (68.49%) |
| Age, mean ± SD                   | 54.29 ± 15.68 |
| Age range                        | 22–83   |
| Sex, n (%)                       |         |
| Female                           | 50 (68.49%) |
| Male                             | 23 (31.51%) |
| BMI (kg/m²)                      | 21.28 ± 0.49 |
| Alcohol drinking, n (%)          | 3 (4.11%) |
| Smoking, n (%)                   | 7 (9.59%) |
| mPAP range (mm Hg)               | 27–108  |
| clinical classification of PH, n (%) |         |
| PAH                              | 35 (47.95%) |
| PH due to left heart disease      | 4 (5.48%) |
| PH due to lung disease and/or hypoxia | 9 (12.33%) |
| PH due to pulmonary artery obstructions | 7 (9.59%) |
| PH with unclear and/or multifactorial mechanisms | 18 (24.66%) |
| WHO-FC III/IV, n (%)             | 67 (91.78%) |

BMI = body mass index, mPAP = mean pulmonary artery pressure, PAH = pulmonary arterial hypertension, PH = pulmonary hypertension, SD = standard deviation, WHO-FC = World Health Organization functional class.

### Table 2
Comparison of clinical characteristics before and after tolvaptan treatment.

| Parameters                  | Before tolvaptan treatment | After tolvaptan treatment | t value  | P value |
|-----------------------------|----------------------------|----------------------------|----------|---------|
| Hb (g/dL)                   | 13.88 ± 16.32              | 12.00 ± 4.06               | 1.164    | .249    |
| ALT (IU/L)                  | 19.74 ± 2.79               | 20.87 ± 1.76               | .575     | .568    |
| AST (IU/L)                  | 29.55 ± 4.07               | 26.19 ± 1.54               | .905     | .369    |
| TBIL (µmol/L)               | 31.86 ± 3.79               | 24.67 ± 2.55               | 3.440    | .001    |
| DBIL (µmol/L)               | 16.34 ± 2.60               | 13.49 ± 1.88               | 2.441    | .018    |
| TBA(µmol/L)                 | 12.25 ± 3.53               | 13.50 ± 3.56               | .577     | .567    |
| UA (µmol/L)                 | 525.9 ± 22.99              | 445.3 ± 26.18              | 3.803    | <.0001  |
| BUN (mmol/L)                | 8.93 ± 0.68                | 9.28 ± 0.84                | .658     | .513    |
| Scr (µmol/L)                | 84.63 ± 4.47               | 89.97 ± 5.51               | 1.430    | .158    |
| Cystatin C (mg/L)           | 1.13 ± 0.07                | 1.43 ± 0.09                | 1.882    | .067    |
| NT-proBNP (pg/mL)           | 4396 ± 594.90              | 2974 ± 436.00              | 2.321    | .023    |
| K⁺ (mEq/L)                  | 4.03 ± 0.07                | 4.27 ± 0.06                | 2.529    | .002    |
| Na⁺ (mEq/L)                 | 140.0 ± 0.58               | 141.3 ± 0.57               | 1.840    | .070    |
| Cl⁻ (mEq/L)                 | 103.6 ± 0.67               | 103.6 ± 0.71               | .019     | .985    |
| Ca⁺⁺ (mEq/L)                | 2.27 ± 0.02                | 2.32 ± 0.02                | 1.945    | .056    |

ALT = alanine aminotransferase, AST = aspartate aminotransferase, BUN = blood urea nitrogen, DBIL = direct bilirubin, Hb = hemoglobin, NT-proBNP = N-terminal pro-brain natriuretic peptide, Scr = serum creatine, TBA = total bile acid, TBL = total bilirubin, UA = uric acid.

### Table 3
Comparison of heart rate and blood pressure before and after tolvaptan treatment.

| Parameters | Before tolvaptan treatment | After tolvaptan treatment | t value  | P value |
|------------|----------------------------|---------------------------|----------|---------|
| HR (bpm)   | 86.86 ± 1.75               | 86.74 ± 1.64              | .059     | .953    |
| SBP (mm Hg) | 109.2 ± 1.94              | 106.0 ± 1.64              | 1.943    | .070    |
| DBP (mm Hg) | 68.29 ± 1.35              | 64.15 ± 1.20              | 3.502    | .0008   |
| MAP (mm Hg) | 81.94 ± 1.33              | 78.12 ± 1.19              | 3.329    | .001    |

DBP = diastolic blood pressure, HR = heart rate, MAP = mean arterial pressure, SBP = systolic blood pressure.
### 5. Conclusions

Adding TLV to targeted drug and traditional diuretic therapies has promising effectiveness for treating PH.

### Author contributions

Qiaoli Chen conceived this study. Qiaoli Chen and Heng Luo collected and analyzed data. Qiaoli Chen wrote the manuscript. Yuping Li supervised this work. All authors have read and approved the final manuscript.

### Data curation: Qiaoli Chen, Heng Luo.

### Project administration: Yuping Li.

### Supervision: Yuping Li.

### Writing – original draft: Qiaoli Chen.

### References

[1] Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.

[2] Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4:306–22.

[3] Sarah B, Ashrith G, Sandeep S. Evaluation, diagnosis, and classification of pulmonary hypertension. Methodist Debakey Cardiovasc J. 2021;17:86–91.

[4] Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–32.

[5] Kinugawa K, Sato N, Inomata T. Effects of Tolvaptan on volume overload in patients with heart failure. Int Heart J. 2018;59:1368–77.

[6] Sakaida I, Terai S, Kurosaki M, et al. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study). J Gastroenterol. 2020;55:800–10.

[7] Lawless SJ, Thompson C, Garrahy A. The management of acute and chronic hyponatraemia. Ther Adv Endocrinol Metab. 2022;13:20420188221097343.

[8] Raina B, Chakraborty R, DeCoy ME, et al. Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression. Pediatr Res. 2021;89:894–9.

[9] Tanaka N, Dan K, Maeda T, et al. Clinical effects of early and short-term Tolvaptan administration in patients hospitalized for acute decompensated heart failure. Cardiology. 2021;146:739–47.

[10] Tamura Y, Kimura M, Takei M, et al. Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. Eur Respir J. 2015;46:283–6.

[11] Vonk NA, Groeneveldt JA, Bogaard HJ. Pulmonary hypertension. Eur Respir Rev. 2016;25:4–11.

[12] Ruoop NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327:1379–91.

[13] Duran A, Mandras S. Pulmonary hypertension in heart failure. Curr Opin Cardiol. 2021;36:205–10.

[14] Konstam MA, Kiernan MS, Bernstein D, et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018;137:e573–622.

[15] Pfister R, Scholz M, Wielckens K, et al. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail. 2004;6:289–93.

[16] El RR, Tallima H. Physiological functions and pathogenic potential of uric acid: a review. J Adv Res. 2017;8:487–93.

[17] Simpson CE, Danico RL, Hummers L, et al. Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. Pulm Circ. 2019;9:2045894019859477.

[18] Saito Y, Tanaka A, Node K, et al. Uric acid and cardiovascular disease: a clinical review. J Cardiol. 2021;78:51–7.

[19] Kumric M, Borovac J, Kurir TT, et al. Clinical implications of uric acid in heart failure: a comprehensive review. Life (Basel) 2021;11:53.

[20] Savale L, Akagi S, Tu L, et al. Serum and pulmonary uric acid in pulmonary arterial hypertension. Eur Respir J. 2021;58:2000332.

[21] Uk KT, Park KY, Kim HJ, et al. Association of hyperuricemia and pulmonary hypertension: a systematic review and meta-analysis. Mod Rheumatol. 2019;29:1031–41.

[22] Yan L, Huang Z, Zhao Z, et al. The prognostic impact of serum uric acid on disease severity and 5-year mortality in patients with idiopathic pulmonary artery hypertension. Front Med (Lausanne). 2022;9:805415.

[23] Bellos I. Safety profile of Tolvaptan in the treatment of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag. 2021;17:649–56.

[24] Tian Y, Chen Y, Deng B, et al. Serum uric acid as an index of impaired renal function in congestive heart failure. J Geriatr Cardiol. 2012;9:137–42.

[25] Seppen J, Bosma P. Bilirubin, the gold within. Circulation. 2012;126:2547–9.

[26] Shiomura R, Kobayashi N, Shirakabe A, et al. Systolic blood pressure and cardiac mortality related to serum total bilirubin levels at admission in patients with acute heart failure. Heart Vessels. 2021;36:69–75.

[27] Gong JN, Zhai ZG, Yang YH, et al. Serum Bilirubin and 6-min walk distance as prognostic predictors for inoperable chronic thromboembolic pulmonary hypertension: a prospective cohort study. Chin Med J (Engl). 2015;128:3125–31.

[28] Xu XQ, Lv ZC, Liu QQ, et al. Direct bilirubin: a new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension. Int J Cardiol. 2017;228:895–9.

[29] Muto S, Okada T, Yasuda M, et al. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial. Drug Healthc Patient Saf. 2017;9:93–104.

| Parameters                      | Before tolvaptan treatment | After tolvaptan treatment | t value | P value  |
|--------------------------------|---------------------------|---------------------------|---------|---------|
| Water intake (mL)              | 1044 ± 67.91              | 1634 ± 60.76              | 6.986   | <.0001  |
| Urine volume (mL)              | 1271 ± 100.60             | 1961 ± 99.50              | 5.633   | <.0001  |
| Body weight (kg)               | 57.94 ± 1.70              | 54.68 ± 1.59              | 5.731   | <.0001  |